Targeted Screening for Transthyretin Amyloid Cardiomyopathy in Patients With Atrial Fibrillation.

Keywords: amyloidosis; atrial fibrillation; atrial flutter; hypertrophy, left ventricular EN amyloidosis atrial fibrillation atrial flutter hypertrophy, left ventricular 1730 1732 3 11/29/22 20221129 NES 221129 Atrial fibrillation (AF) and atrial flutter (AFL) are common in patients with transthyretin cardiac amyloidosis (ATTR-CM) and can present years before diagnosis of ATTR-CM.[1] Prior data from our amyloidosis center, which serves both urban and rural parts of the Pacific Northwest, demonstrated an AF/AFL prevalence of 73% among patients with wild type or hereditary ATTR-CM2 - a treatable cause of heart failure if recognized in a timely fashion.[3] Technetium-99m pyrophosphate scintigraphy (Tc-99m PYP) is a simple, noninvasive diagnostic option[3] that allows for screening of ATTR-CM in broader populations, however, there is paucity of data regarding screening for ATTR-CM in patients with AF/AFL. Footnotes 1 Nonstandard Abbreviations and Acronyms AF atrial fibrillation AFL atrial flutter ATTR-CM transthyretin cardiac amyloidosis LV left ventricular LVH left ventricular hypertrophy Tc-99m PYP technetium-99m pyrophosphate scintigraphy 2 For Sources of Funding and Disclosures, see page 1732. Graph In the present study, where systematic screening for ATTR-CM in patients with LVH and AF/AFL was instituted, routine screening of more than 1600 AF/AFL patients resulted in 65 patients undergoing Tc-99m PYP - of which only 1 patient was diagnosed with ATTR-CM. [Extracted from the article]